Skip to Main Content

A panel of European drug reviewers notified Biogen that its Alzheimer’s treatment Aduhelm is unlikely to win approval there, the company announced Wednesday.

Aduhelm received a “negative trend vote” from experts at the European Medicines Agency, following a type of hearing called an oral explanation.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment